EGFR and non-small cell lung carcinoma: Previous studies have reported that EA acts as a dual inhibitor of GST and WNT, and afatinib can inhibit EGFR family, and so we examined whether the combination of EA and afatinib has enhanced antitumor effects in NSCLC by suppressing EGFR and WNT signaling pathways.